Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 18/20 | 1.00 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | APAF1 | O14727 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | F3 | P13726 | 6/20 | 0.87 |
| ▸ | DRD3 | P35462 | 6/20 | 0.81 |
| ▸ | DRD5 | P21918 | 3/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.81 |
| ▸ | DRD4 | P21917 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Discretamine SCHEMBL13885928 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Scoulerine SCHEMBL29617585 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Discretamine SCHEMBL29362664 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Scoulerine SCHEMBL29462969 | 1.00 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Discretamine SCHEMBL4202179 | 0.99 | DRD1 (0.98) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Tetrahydropalmatrubine SCHEMBL20759895 | 0.93 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| Tetrahydropalmatrubine SCHEMBL12904352 | 0.93 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| SCHEMBL680031 | 0.90 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| SCHEMBL29561422 | 0.90 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 | |
| SCHEMBL14703846 | 0.90 | DRD1 (1.00) | DRD1DRD2KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 395 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| WO-2025031833-A1 | RECOMBINANT STRAIN AND USE THEREOF IN PRODUCTION OF SCOULERINE | CHRYSEA LIMITED (IE) | 2025-02-13 | — | — | WO | claimed |
| US-20240415129-A1 | BOTANICAL BASED BIO-INSECTICIDAL COMPOSITIONS FOR CONTROLLING PESTS AND IMPROVING THE PLANT PHYSIOLOGICAL PROCESS | KAY BEE BIO ORGANICS PVT LTD (IN) | 2024-12-19 | — | — | US | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| US-12091696-B2 | O-methyltransferase protein with highly specific catalytic function for multiple bias parent nuclei and encoding gene and use thereof | INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) | 2024-09-17 | — | — | US | claimed |
| US-20240240194-A1 | TRANSCRIPTION FACTOR | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2024-07-18 | — | — | US | claimed |
| EP-4347846-A1 | TRANSCRIPTION FACTOR | Sun Pharmaceutical Industries Australia PTY Limited (AU) | 2024-04-10 | — | — | EP | claimed |
| US-20240052388-A1 | O-METHYLTRANSFERASE PROTEIN WITH HIGHLY SPECIFIC CATALYTIC FUNCTION FOR MULTIPLE BIAS PARENT NUCLEI AND ENCODING GENE AND USE THEREOF | INSTITUTE OF CHINESE MATERIA MEDICA CHINA ACADEMY OF CHINESE MEDICAL SCIENCES (CN) | 2024-02-15 | — | — | US | claimed |
| WO-2024015152-A1 | TETRAHYDROPAPAVERINE-PRODUCING MICROBES AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-01-18 | — | — | WO | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| CN-102078319-A | Application of dehydrocorydaline and scoulerine to medicament production | UNIV SUN YAT SEN | 2011-06-01 | — | — | CN | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-20090036387-A1 | NOVEL CHEMICAL ENTITIES AFFECTING NEUROBLASTOMA TUMOR-INITIATING CELLS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2009-02-05 | — | — | US | claimed |
| US-20080176754-A1 | COMPOSITIONS AND METHODS FOR PRODUCING BENZYLISOQUINOLINE ALKALOIDS | HERCULES CAPITAL, INC., AS AGENT | 2008-07-24 | — | — | US | claimed |
| WO-2008067070-A2 | COMPOSITIONS AND METHODS FOR PRODUCING BENZYLISOQUINOLINES ALKALOIDS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-06-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885KDM4E 4729/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | DRD1 213/4885DRD2 85/4885KDM4E 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.